XORTX Therapeutics (XRTX) Amortizatization of Intangibles (2020 - 2026)
XORTX Therapeutics (XRTX) posted Amortizatization of Intangibles of $3460.0 for Q1 2026, down 96.25% on a QoQ basis from $92308.0 in Q4 2025, and down 46.94% year-over-year from $6521.0 in Q1 2025.
XORTX Therapeutics (XRTX) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
XORTX Therapeutics' Amortizatization of Intangibles history runs 7 years deep, the most recent figure standing at $3460.0 for Q1 2026.
- Quarterly Amortizatization of Intangibles fell 46.94% year-over-year to $3460.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $109054.0 (down 2.55% YoY) and the FY2025 annual result came in at $112115.0, down 4.4% from the prior year.
- Amortizatization of Intangibles was $3460.0 for Q1 2026 at XORTX Therapeutics, down from $92308.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $92835.0 in Q4 2024 and bottomed at -$1862.0 in Q3 2023.
- A 5-year average of $25269.0 and a median of $6789.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- Peak annual rise in Amortizatization of Intangibles reached 1191.36% in 2023, while the deepest fall reached 106.71% in 2023.
- XORTX Therapeutics' Amortizatization of Intangibles stood at $21544.9 in 2022, then soared by 267.25% to $79123.0 in 2023, then gained by 17.33% to $92835.0 in 2024, then fell by 0.57% to $92308.0 in 2025, then tumbled by 96.25% to $3460.0 in 2026.
- Business Quant data shows XRTX's Amortizatization of Intangibles at $3460.0 in Q1 2026, $92308.0 in Q4 2025, and $6497.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | XORTX Therapeutics | 2.91 Bn | 2.91 Bn | - | 3,460.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,460.00 |
| Mar 31, 2026 | 3,460.00 |
| Dec 31, 2025 | 92,308.00 |
| Dec 31, 2025 | 92,308.00 |
| Sep 30, 2025 | 6,497.00 |
| Sep 30, 2025 | 6,497.00 |
| Jun 30, 2025 | 6,789.00 |
| Jun 30, 2025 | 6,789.00 |
| Mar 31, 2025 | 6,521.00 |
| Mar 31, 2025 | 6,521.00 |
| Dec 31, 2024 | 92,835.00 |
| Dec 31, 2024 | 92,835.00 |
| Sep 30, 2024 | 6,389.00 |
| Sep 30, 2024 | 6,389.00 |
| Jun 30, 2024 | 6,164.00 |
| Jun 30, 2024 | 6,164.00 |
| Mar 31, 2024 | 11,886.00 |
| Mar 31, 2024 | 11,886.00 |
| Dec 31, 2023 | 79,123.00 |
| Dec 31, 2023 | 79,123.00 |